Major depressive disorder: Remission of associated symptoms

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 6, 2006, Pages 27-32

  Trivedi, Madhukar H ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DULOXETINE; FLUOXETINE; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MOOD; MORBIDITY; MORTALITY; NERVE TRACT; NORADRENERGIC SYSTEM; PAIN; PATHOGENESIS; PATIENT COMPLIANCE; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; NOREPINEPHRINE; PHYSICIAN'S PRACTICE PATTERNS; REMISSION INDUCTION; SEROTONIN; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 33746054954     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Wells KB, Rogers W, Burnam A, et al. How the medical comorbidity of depressed patients differs across health care settings: results from the Medical Outcomes Study. Am J Psychiatry 1991;148:1688-1696
2. Vuorilehto M, Melartin T, Isometsa E. Depressive disorders in primary care: recurrent, chronic, and co-morbid. Psychol Med 2005;35:673-682
3. Coulehan JL, Schulberg HC, Block MR, et al. Medical comorbidity of major depressive disorder in a primary medical practice. Arch Intern Med 1990;150:2363-2367
4. Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990;51(6, suppl):3-11; discussion 12-14
5. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-226
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000
7. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
8. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
9. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-2445
10. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335
11. Schappert SM. National Ambulatory Medical Care Survey: 1989 summary. Vital Health Stat 13 1992:1-80
12. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental services in the United States: results from the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62:629-640
13. Wang PS, Berglund P, Olfson M, et al. Failure and delay in treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:603-613
14. Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741
15. Clinical Practice Guideline, Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, MD: US Dept Health Human Services, Agency for Health Care Policy and Research; April 1993. AHCPR publication 93-0551
16. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000;14:3-20
17. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders, II: principles of management. Can J Psychiatry 2001;46 (suppl 1):21S-28S
18. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
19. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
20. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046-1052
21. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619
22. Murphy JM, Monson RR, Olivier DC, et al. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987;44:473-480
23. Everson SA, Roberts RE, Goldberg DE, et al. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998;158:1133-1138
24. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-942
25. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-630
26. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-1825
27. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-227
28. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001;38:199-205
29. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1466-1474
30. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997;45:5-17; discussion 17-18
31. Vergouwen AC, Bakker A, Katon WJ, et al. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry 2003;64:1415-1420
32. Streja DA, Hui RL, Streja E, et al. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Manag Care 1999;5:1133-1142
33. Haslam C, Brown S, Atkinson S, et al. Patients' experiences of medication for anxiety and depression: effects on working life. Fam Pract 2004;21:204-212
34. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74
35. Manning C, Marr J., "Real-life burden of depression" surveys: GP and patient perspectives on treatment and management of recurrent depression. Curr Med Res Opin 2003;19:526-531
36. Denninger JW, Mahal Y, Merens W, et al. The relationship between somatic symptoms and depression. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 21, 2002; Philadelphia, Pa. Abstract NR251:68
37. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193-207
38. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651-660
39. Seminowicz DA, Mayberg HS, McIntosh AR, et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 2004;22:409-418
40. Lieberman JA. History of the use of antidepressants in primary care. Prim Care Companion J Clin Psychiatry 2003;5(suppl 7):6-10
41. Mayberg HS. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003;13:805-815
42. Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004;61:34-41
43. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001;286:2947-2955
44. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004;19:813-818
45. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
46. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28
47. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53
48. Mallinckrodt CH, Goldstein DJ, Detke MJ, et al. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19-28
49. Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. 3rd ed. New York City, NY: Elsevier, 1991
50. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005;52(suppl):284-290
51. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005;6:2091-2101
52. Uzun S, Kozumplik O, Mimica N, et al. Aripiprazole: an overview of a novel antipsychotic. Psychiatr Danub 2005;17:67-75
53. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs 2001;10:1789-1796
54. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999;111:22-34
55. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron 2002;34:13-25
56. Richelson E. Review of antidepressants in the treatment of mood disorders. In: Dunner DL, Fetcher J, Lefebvre Y, eds. Current Psychiatric Therapy. Philadelphia, Pa: WB Saunders Company; 1993:232-239
57. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220
58. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;61(suppl 1):5-12